Steven Kelly
Vermögen: 64 $ am 31.05.2026
Vermögen: 64 $ am 31.05.2026
Steven Kelly is the founder of CTx Operations, Inc., founded in 2018, holding the titles of President, Chief Executive Officer & Director.
Mr. Kelly currently works as an Independent Director at Artelo Biosciences, Inc. since 2017.
Former jobs include President & Chief Executive Officer at Innovive Pharmaceuticals, Inc. from 2004 to 2010; President & Chief Executive Officer at Pinteon Therapeutics, Inc. from 2014 to 2015; Chief Executive Officer at Theracrine, Inc. from 2011 to 2012; Chief Executive Officer at Carisma Therapeutics, Inc. from 2025 to 2026; President, Chief Executive Officer & Director at Carisma Therapeutics, Inc. from 2018 to 2025; Chief Commercial Officer at BioVex, Inc. from 2010 to 2011; and Principal at Kelly Bioconsulting LLC from 2012 to 2018.
Education includes an MBA from Cornell University and an undergraduate degree from the University of Oregon.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.02.2026 | 46 ( 0% ) | 64 $ | 31.05.2026 | |
| 31.05.2025 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ARTELO BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 02.05.2017 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Gründer | 23.04.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Vorstandsvorsitzender | 01.01.2026 |
| CARISMA THERAPEUTICS, INC. | Vorstandsvorsitzender | 15.11.2025 |
Kelly Bioconsulting LLC
Kelly Bioconsulting LLC Miscellaneous Commercial ServicesCommercial Services Provides business consulting services | Corporate Officer/Principal | 01.01.2018 |
Pinteon Therapeutics, Inc.
Pinteon Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Vorstandsvorsitzender | 01.07.2015 |
Theracrine, Inc.
Theracrine, Inc. BiotechnologyHealth Technology Develops anti-metastatic drugs for cancer therapeutics | Vorstandsvorsitzender | 01.08.2012 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases | Health Technology |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
Pinteon Therapeutics, Inc.
Pinteon Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Artelo Biosciences, Inc.
Artelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops endocannabinoid system modulating therapeutics | Health Technology |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oregon
University of Oregon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Theracrine, Inc.
Theracrine, Inc. BiotechnologyHealth Technology Develops anti-metastatic drugs for cancer therapeutics | Health Technology |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Health Technology |
Kelly Bioconsulting LLC
Kelly Bioconsulting LLC Miscellaneous Commercial ServicesCommercial Services Provides business consulting services | Commercial Services |
Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen